Switch theme
Sign up to access all valuation multiples
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company’s operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
2017
142
Last FY Revenue n/a
LTM EBITDA -$306M
$4.3B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Nuvalent has a last 12-month revenue (LTM) of n/a and a last 12-month EBITDA of -$306M.
In the most recent fiscal year, Nuvalent achieved revenue of n/a and an EBITDA of -$280M.
Nuvalent expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Nuvalent valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | -$0.4M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$306M | XXX | -$280M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$323M | XXX | -$280M | XXX | XXX | XXX |
| EBIT Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$300M | XXX | -$261M | XXX | XXX | XXX |
| Net Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Nuvalent's stock price is $75.
Nuvalent has current market cap of $5.4B, and EV of $4.3B.
See Nuvalent trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $4.3B | $5.4B | XXX | XXX | XXX | XXX | $-4.33 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Nuvalent has market cap of $5.4B and EV of $4.3B.
Nuvalent's trades at n/a EV/Revenue multiple, and -15.3x EV/EBITDA.
Equity research analysts estimate Nuvalent's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Nuvalent has a P/E ratio of -17.8x.
See valuation multiples for Nuvalent and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $5.4B | XXX | $5.4B | XXX | XXX | XXX |
| EV (current) | $4.3B | XXX | $4.3B | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | -14.0x | XXX | -15.3x | XXX | XXX | XXX |
| EV/EBIT | -13.2x | XXX | -15.3x | XXX | XXX | XXX |
| EV/Gross Profit | -10489.4x | XXX | n/a | XXX | XXX | XXX |
| P/E | -17.8x | XXX | -20.5x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -23.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialNuvalent's revenue per employee in the last FY averaged n/a, while opex per employee averaged $2.0M for the same period.
Nuvalent's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Nuvalent's rule of X is n/a (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Nuvalent and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | 22% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $2.0M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Nuvalent acquired XXX companies to date.
Last acquisition by Nuvalent was XXXXXXXX, XXXXX XXXXX XXXXXX . Nuvalent acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Nuvalent founded? | Nuvalent was founded in 2017. |
| Where is Nuvalent headquartered? | Nuvalent is headquartered in United States of America. |
| How many employees does Nuvalent have? | As of today, Nuvalent has 142 employees. |
| Who is the CEO of Nuvalent? | Nuvalent's CEO is Dr. James R. Porter, PhD. |
| Is Nuvalent publicy listed? | Yes, Nuvalent is a public company listed on NAS. |
| What is the stock symbol of Nuvalent? | Nuvalent trades under NUVL ticker. |
| When did Nuvalent go public? | Nuvalent went public in 2021. |
| Who are competitors of Nuvalent? | Similar companies to Nuvalent include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Nuvalent? | Nuvalent's current market cap is $5.4B |
| Is Nuvalent profitable? | Yes, Nuvalent is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Nuvalent? | Nuvalent's last 12 months EBITDA is -$306M. |
| What is the current EV/EBITDA multiple of Nuvalent? | Current EBITDA multiple of Nuvalent is -14.0x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
